July 17, 2017

PRNewswire/ New market research titled Autism – Pipeline Review, H2 2015 is a report providing data and information that helps strengthen autism R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on autism pipeline spread across 131 pages, analyzing 19 companies, 30+ drug profiles and supported with 39 tables and 16 figures is now available at http://www.reportsnreports.com/reports/423135-autism-pipeline-review-h2-2015.html .

This report provides comprehensive information on Autism pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. This autism pipeline report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the autism pipeline report may be removed or altered based on the availability and relevance of data for the indicated disease.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. This autism pipeline report and other pipeline research studies are built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in this autism pipeline report and other pipeline studies undergo periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this autism pipeline H2 2015 review report include Addex Therapeutics Ltd, BioCrea GmbH, BrainStorm Cell Therapeutics Inc., Cellceutix Corporation, Confluence Pharmaceuticals LLC, Curemark, LLC, Egenix, Inc., F. Hoffmann-La Roche Ltd., Heptares Therapeutics Limited, Intra-Cellular Therapies, Inc., MedDay, Merz Pharma GmbH & Co. KgaA, Mnemosyne Pharmaceuticals, Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Retrophin Inc., Reviva Pharmaceuticals Inc., Saniona AB and Sumitomo Dainippon Pharma Co., Ltd. Drug profiles mentioned in this autism pipeline research with their product description and other details include (dextromethorphan hydrobromide + quinidine sulfate), acamprosate calcium, ADX-71441, ADX-88178, aripiprazole, carbetocin, CM-AT, CN-2097, Drug for Autism, HTL-14242, ITI-007, KM-391, lurasidone hydrochloride, MD-1103, memantine hydrochloride, oxytocin, RG-7314, RO-5285119, RP-5063, Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism, Small Molecule to Modulate GABRA5 Receptor for CNS Disorders, Small Molecule to Target GPR63 for Autism, Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism, Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders, Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome, Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism, Small Molecules to Target Oxytocin for Autism and Anxiety Disorders, Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia, Stem Cell Therapy for Neurodegenerative Disorders, suramin hexasodium and VU-0410120. Order a copy of Autism – Pipeline Review, H2 2015 market research report at http://www.reportsnreports.com/Purchase.aspx?name=423135 .

The report provides a snapshot of the global therapeutic landscape of Autism and reviews key autism pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report also reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects while summarizing all the dormant and discontinued autism pipeline projects. A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, autism pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals related to autism pipeline products are also mentioned in this autism therapeutic pipeline review report.

Another newly published market research titled Nocturia – Pipeline Review, H2 2015 is a report that provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies and helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. The research helps develop strategic initiatives by understanding the focus areas of leading companies, identify and understand important and diverse types of therapeutics under development for Nocturia as well as plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics as well as develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope with the help of this nocturia pipeline review report of 38 pages available at http://www.reportsnreports.com/reports/423142-nocturia-pipeline-review-h2-2015.html .

Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

Source: PR Newswire: Autism Pipeline Review H2 2015 Therapeutic Report: http://www.prnewswire.com/news-releases/autism-pipeline-review-h2-2015-therapeutic-report-527897561.html


About the author 

Press Release

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}


December 24, 2020

From YouTube The United States Senate unanimously passed

November 6, 2020

Liver transplant potentially helpful in rare form of

October 6, 2020

New research conducted by a group of occupational

September 23, 2020

Pain may predict sleeping problems in teens diagnosed

July 29, 2020

Autism Hampshire, UK – teams have been invited

July 15, 2020

A study published in The American Journal of

July 11, 2020

This is part 2 of our review of

June 22, 2020

It may seem like a pipe dream: a